A Phase 2 interventional study of ¹⁸F-Fluoromisonidazole and Computed Tomography in IDH Wild Type Glioblastoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by OHSU Knight Cancer Institute · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 225th largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 49 that started in 2019, is one of 396 in phase 2, reaches primary completion later than 257 of the 321 other live ones, and was the 876th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Barbara Ann Karmanos Cancer Institute · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 341 Glioblastoma studies recruiting now, 236 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 671 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 49 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 77 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,155 interventional studies, 60 across the 79 observational. Of the 883 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,302 have an industry lead sponsor. The 10 most frequent:
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 43 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
OHSU Knight Cancer Institute has 4 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
104 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 104 to your calendar (.ics) → With an account.
Among the 1,302 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well 18F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. Two contrast agents called gadolinium and ferumoxytol are used during some of the MRI scans. A contrast agent is a liquid-like dye that is given intravenously (IV) to help imaging machines create pictures. The study drug, called FMISO, provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
PRIMARY OBJECTIVES:
I. Determine the feasibility of obtaining 18F-fluoromisonidazole (FMISO) PET (hypoxic volume and tumor to blood background values [T/B]) and dynamic susceptibility contrast enhanced (DSC), diffusion-weighted imaging (DWI), \& segregation \& extravascular localization of ferumoxytol imaging (SELFI) MRI measures in patients with intracranial brain tumors.
II. Determine if MRI contrast-enhancement and hypoxic volume are imaging profiles of glioblastoma immunotherapy-mediated pseudoprogression or true progression in a clinical trial.
III. Determine if SELFI hypoxic fraction are imaging biomarkers of glioblastoma neuroinflammation.
SECONDARY OBJECTIVES:
I. Determine the feasibility of baseline and follow-up ferumoxytol (Fe)-enhanced FMISO PET and MR imaging co-registration.
II. Assess diagnostic performance of imaging metrics to identify failed therapy at earlier imaging timepoints before presumed progression.
III. Determine the reliability of the pre-therapy FMISO PET imaging metrics as assessed by baseline "test" and "retest experiments.
IV. Compare the diagnostic performance of SELFI hypoxic fraction to Modified Response Assessment in Neuro-Oncology (mRANO) criteria.
V. Determine the sensitivity and specificity of SELFI hypoxic fraction for the diagnosis of neuroinflammation and recurrent disease.
VI. Assess progression free survival. VII. Assess overall survival. VIII. Determine change in imaging metrics from post-therapy and disease progression in differentiating neuroinflammation from recurrent disease.
IX. Determine optimal SELFI hypoxic fraction imaging parameters. X. Correlate SELFI hypoxic fraction with innate immune phenotype and hypoxia expression.
TERTIARY OBJECTIVE:
I. Determine the reproducibility of the baseline FMISO PET imaging metrics as assessed by baseline "test" and "retest" experiments.
OUTLINE:
Participants receive FMISO and/or FE IV. Patients also undergo dynamic PET/computed tomography (CT) or PET/MRI over 120 minutes beginning 1 minute prior to FMISO injection, and static PET/CT or PET/MRI over 20-40 minutes approximately 90 minutes after FMISO injection. Participants may then receive FMISO and/or Fe IV and gadolinium IV and undergo PET/MRI scan, followed by an additional PET/MRI scan without FMISO and/or Fe and gadolinium the following day. These scans may repeat every 4 weeks up to 4 times. Supplemental oxygen may be administered to affect MRI signal change.
After conclusion of the diagnostic tests, participants are followed for up to 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive FMISO and/or FE IV. Patients also undergo dynamic PET/CT or PET/MRI over 120 minutes beginning 1 minute prior to FMISO injection, and static PET/CT or PET/MRI over 20-40 minutes approximately 90 minutes after FMISO injection. Participants may then receive FMISO and/or Fe IV and gadolinium IV and undergo PET/MRI scan, followed by an additional PET/MRI scan without FMISO and/or Fe and gadolinium the following day. These scans may repeat every 4 weeks up to 4 times. Supplemental oxygen may be administered to affect MRI signal change.
Drug: ¹⁸F-Fluoromisonidazole · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Procedure: Oxygen Therapy · Drug: Ferumoxytol · Drug: Gadolinium
Given IV
Also known as: ¹⁸F-MISO, ¹⁸F-Misonidazole, FMISO
Undergo PET/CT
Also known as: CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
Undergo PET/MRI or PET/CT
Also known as: Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), NMRI, Nuclear Magnetic Resonance Imaging
Undergo PET/MRI
Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Receive supplemental oxygen
Also known as: supplemental oxygen therapy
Given IV
Also known as: Feraheme, Ferumoxytol, ferumoxytol, FERUMOXYTOL NON-STOICHIOMETRIC MAGNETITE, Ferumoxytol Non-Stoichiometric Magnetite
Given IV
Successful production of images
Assessed as a factor of generating quantitative positron emission tomography (PET)/magnetic resonance imaging (MRI) metrics (intra-tumoral FMISO tumor to blood \[T/B\] level, hypoxic volume, dynamic susceptibility contrast enhanced \[DSC\], diffusion-weighted imaging \[DWI\], and segregation \& extravascular localization of ferumoxytol imaging \[SELFI\] values, and tissue oxygen maps). Images generated during the administration of oxygen will be used to generate tissue oxygen maps of the brain. Following completion of cohort enrollment, the generation of each quantitative PET/MRI metric will be independently scored as a dichotomous variable; successful or non-successful. Proportional assessment will be performed to assess for project feasibility. The estimated proportion of success rate for each metric along with the corresponding 95% binomial confidence interval will be provided.
Time frame: Two days of diagnostic imaging
SELFI and hypoxic fraction, and T1 ferumoxytol Fe/gadolinium (Gd) log mismatch ratio in patients receiving immunotherapy
Diagnostic performance of PET/MRI metrics (SELFI and hypoxic fraction) and Gd\_MRI to differentiate progression from neuroinflammation (pseudoprogresion) will be evaluated using sensitivity, specificity and area under the receiver operating curve (AUROC). Sensitivity and specificity will be characterized using proportions and exact 95% confidence intervals. Difference in diagnostic performance between PET/MRI metrics (SELFI and hypoxic fraction) and Gd\_MRI will be assessed using McNemar's test to compare sensitivity and specificity and using the DeLong test to compare AUROC.
Time frame: Two days of diagnostic imaging at time of suspected progression
SELFI and hypoxic fraction, and T1 ferumoxytol Fe/gadolinium (Gd) log mismatch ratio in all patients
Diagnostic performance of PET/MRI metrics (SELFI and hypoxic fraction) and Gd\_MRI to differentiate progression from neuroinflammation (pseudoprogresion) will be evaluated using sensitivity, specificity and AUROC. Sensitivity and specificity will be characterized using proportions and exact 95% confidence intervals. Difference in diagnostic performance between PET/MRI metrics (SELFI and hypoxic fraction) and Gd\_MRI will be assessed using McNemar's test to compare sensitivity and specificity and using the DeLong test to compare AUROC.
Time frame: Two days of diagnostic imaging at time of suspected progression
Successful co-registration (Yes vs. No)
The generation of co-registered imaging data sets will be independently scored as a dichotomous variable; successful or non-successful (\< 10mm versus \[vs.\] \> 10mm alignment error). Proportional assessment will be performed to assess for project feasibility. The estimated proportion along with the corresponding 95% binomial confidence interval will be provided.
Time frame: Baseline to the start of long-term follow-up (up to 5 years)
T/B value and hypoxic tumor volume
Tumor-to-background ratio (TBR) is calculated by dividing the tumor SUV by the mean SUV of the background region, using either voxelwise values or summary measures such as SUVmean. To define hypoxic volume, a threshold-based approach is applied in which all tumor voxels with FMISO uptake above a predetermined TBR cutoff are classified as hypoxic; the hypoxic volume is then calculated as the total volume of these above-threshold voxels. Hypoxic volume is measured in mm3.
Time frame: Time Frame: Baseline to the start of long-term follow-up (up to 5 years)
Generation of SELFI Metric
Will assess generation of whole brain SELFI MRI data set. Generation of SELFI MRI: YES/NO.
Time frame: Imaging time points before gadolinium-based contrast agent defined presumed progression, year 1-4
SELFI diagnostic performance of imaging metrics
SELFI metric will be assessed to identify failed therapy at each imaging timepoint. Assessing Failed Therapy: Area Under the Curve for each metric at each time point to diagnose disease progression
Time frame: Imaging time points before gadolinium-based contrast agent defined presumed progression, year 1-4
Generation of Hypoxic Fraction Metric
Will assess generation of hypoxic fraction data set. Generation of hypoxic fraction: MRI YES/NO.
Time frame: Imaging time points before gadolinium-based contrast agent defined presumed progression, year 1-4
Hypoxic Fraction Diagnostic performance of imaging metric
Hypoxic Fraction metric will be assessed to identify failed therapy at each imaging timepoint. Assessing Failed Therapy: Area Under the Curve for each metric at each time point to diagnose disease progression.
Time frame: Imaging time points before gadolinium-based contrast agent defined presumed progression, year 1-4
Hypoxic fraction
Will determine the reproducibility of the pre-therapy FMISO PET imaging metrics as assessed by baseline "test" and "retest experiments. Reproducibility of hypoxic fraction between baseline "test" and "retest experiments will be evaluated by intra-class correlation coefficients (ICC).
Time frame: Retest will be scheduled within 7 days after the initial PET imaging examination, Baseline, year 1-4]
SELFI, hypoxic fraction and Modified Response Assessment in Neuro-Oncology (mRANO) criteria
Sensitivity, specificity and AUROC will be used to determine the diagnostic performance of imaging biomarkers (SELFI and hypoxic fraction, change in SELFI and hypoxic fraction between fraction between post-radiation therapy and suspected disease progression) and mRANO to differentiate progression from neuroinflammation (pseudoprogresion). Optimal cutoff points for SELFI and hypoxic fraction will be identified. Sensitivity and specificity will be characterized using proportions and exact 95% confidence intervals. McNemar's test will be used to compare sensitivity and specificity between imaging biomarkers and mRANO. Comparison of diagnostic performance with Gd MRI may also be explored.
Time frame: Year 1-5 at suspected disease progression
SELFI and hypoxic fraction
Will determine the sensitivity and specificity of SELFI hypoxic fraction for the diagnosis of neuroinflammation and recurrent disease. Sensitivity and specificity will be characterized using proportions and exact 95% confidence intervals. McNemar's test will be used to compare sensitivity and specificity between imaging biomarkers and mRANO. Comparison of diagnostic performance with Gd MRI may also be explored.
Time frame: Year 1-5 at suspected disease progression
Progression free survival (PFS)
Will be analyzed using the Kaplan-Meier product limit methods for all patients, taking censoring into account. A Cox regression model will be used to explore the association between imaging biomarkers and PFS while adjusting for patient characteristics.
Time frame: Date of diagnosis to date of progression, death or end of study, assessed up to 5 years
Overall survival (OS)
Will be analyzed using the Kaplan-Meier product limit methods for all patients, taking censoring into account. A Cox regression model will be used to explore the association between imaging biomarkers and OS while adjusting for patient characteristics.
Time frame: Date of diagnosis to date of progression, death or end of study, assessed up to 5 years
Change in SELFI and hypoxic fraction
Difference of SELFI or hypoxic fraction between post-radiation therapy and suspected disease progression
Time frame: From post-therapy to disease progression/pseudoprogression, year 1-5
SELFI
Will determine optimal SELFI imaging parameters. Outcome Measure: Optimal SELFI imaging echo time (TE) and repetition time (TR). Description: The optimal SELFI imaging parameters will be defined as the echo time (TE) and repetition time (TR) combination that demonstrates the highest correlation coefficient between SELFI and macrophage cellular density measured in tumor tissue samples. Unit of Measure: Milliseconds (ms).
Time frame: Baseline at year 1-3
SELFI and hypoxic fraction
Will assess correlation of SELFI hypoxic fraction with innate immune phenotype and hypoxia expression. Since innate immune phenotype is a binary variable (M1, or M2), differences in imaging metrics between M1 and M2 will be evaluated using two sample t-test. If normal assumption is not satisfied, data transformation, or 95% confidence intervals based on bootstrapping method will be used. Hypoxia expression will be measured by an ordinal variable (0,1,2,3,4) based on CA-9 expression, and correlation between SELFI/hypoxic fraction and hypoxia expression will be evaluated by Spearman's rank correlation coefficient.
Time frame: Year 1-4
Started Jun 2019 (actual). Primary completion is estimated for Jan 2029, 115 months after the start.
Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 115 months is above that.
Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluoromisonidazole
OHSU Knight Cancer Institute →